Browse by UCL people
Group by: Type | Date
Jump to: Article
Number of items: 12.
Article
Al Wattar, BH;
Rogozińska, E;
Vale, C;
Fisher, D;
Petersen, I;
Nicum, S;
Bannington, D;
... Freemantle, N; + view all
(2024)
Effectiveness and safety of menopause treatments: pitfalls of available evidence and future research need.
Climacteric
, 27
(2)
pp. 154-158.
10.1080/13697137.2023.2297880.
|
|
Ledermann, JA;
Matias-Guiu, X;
Amant, F;
Concin, N;
Davidson, B;
Fotopoulou, C;
González-Martin, A;
... Fagotti, A; + view all
(2024)
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Annals of Oncology
, 35
(3)
pp. 248-266.
10.1016/j.annonc.2023.11.015.
|
|
Merry, Eve;
Kesmez, Ronas Taner;
Yu, Tamara;
Flynn, Michael;
Ledermann, Jonathan;
Lockley, Michelle;
Macdonald, Nicola;
... Miller, Rowan; + view all
(2024)
A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population.
International Journal of Gynecological Cancer
10.1136/ijgc-2024-005394.
(In press).
|
 |
|
Moore, KN;
Angelergues, A;
Konecny, GE;
García, Y;
Banerjee, S;
Lorusso, D;
Lee, JY;
... Van Gorp, T; + view all
(2023)
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
New England Journal of Medicine
, 389
(23)
pp. 2162-2174.
10.1056/NEJMoa2309169.
|
|
Morgan, Robert D;
Clamp, Andrew R;
Barnes, Bethany M;
Timms, Kirsten;
Schlecht, Helene;
Yarram-Smith, Laura;
Wallis, Yvonne;
... Jayson, Gordon C; + view all
(2023)
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
International Journal of Gynecological Cancer
10.1136/ijgc-2022-004211.
(In press).
|
|
|
Nicum, Shibani;
Blagden, Sarah P;
(2022)
PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
Clinical Cancer Research
, 28
(11)
pp. 2201-2203.
10.1158/1078-0432.CCR-22-0442.
|
|
Nicum, Shibani;
McGregor, Naomi;
Austin, Rachel;
Collins, Linda;
Dutton, Susan;
McNeish, Iain;
Glasspool, Rosalind;
... Mansouri, Anita; + view all
(2024)
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.
British Journal of Cancer
10.1038/s41416-023-02567-6.
(In press).
|
|
Olawaiye, AB;
Gladieff, L;
O'Malley, DM;
Kim, JW;
Garbaos, G;
Salutari, V;
Gilbert, L;
... Lorusso, D; + view all
(2025)
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
The Lancet
, 405
(10496)
pp. 2205-2216.
10.1016/S0140-6736(25)01040-2.
|
|
Oxley, Samuel;
Kalra, Ashwin;
Sideris, Michail;
Itzkowitz, Nicole;
Evans, Olivia;
Atakpa, Emma Christine;
Brentnall, Adam R;
... Manchanda, Ranjit; + view all
(2023)
Impact of Multiple COVID-19 Waves on Gynaecological Cancer Services in the UK.
Cancers
, 15
(4)
, Article 1273. 10.3390/cancers15041273.
|
|
Pawsey, A;
Mahalingam, P;
Senthivel, N;
Ramessur, A;
Turnbull, E;
Usman, S;
Browne, R;
... Eminowicz, G; + view all
(2025)
Real World Outcomes in Patients With Recurrent, Advanced, or Metastatic Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab.
Clinical Oncology
, 37
, Article 103656. 10.1016/j.clon.2024.10.008.
|
|
Taylor, Alexandra;
Sundar, Sudha S;
Bowen, Rebecca;
Clayton, Rick;
Coleridge, Sarah;
Fotopoulou, Christina;
Ghaem-Maghami, Sadaf;
... Morrison, Jo; + view all
(2022)
British Gynaecological Cancer Society Recommendations for Women With Gynecological Cancer Who Received Non-standard Care During the COVID-19 Pandemic.
Obstetrical and Gynecological Survey
, 77
(3)
pp. 156-157.
10.1097/01.ogx.0000822432.56370.10.
|
|
Vergote, I;
Gonzalez-Martin, A;
Lorusso, D;
Gourley, C;
Mirza, MR;
Kurtz, JE;
Okamoto, A;
... Zhu, J; + view all
(2022)
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
The Lancet Oncology
, 23
(8)
e374-e384.
10.1016/S1470-2045(22)00139-5.
|
